Table 6. Characteristics of studies evaluating the impacts of cannabis use in individuals with Parkinson’s disease.

Number of studies	Designs	Primary studies
		Use type	Funding
15	Systematic review: 5 [36, 42, 48, 53, 58]	Medical, overseen by physician: 5 [65, 66, 79, 131, 149]	Non-industry: 3 [69, 83, 154]
	RCTs: 5 [65, 66, 69, 79, 83]	Medical, not prescribed: 1 [154]	Mixed (industry and non-industry): 1 [79]
	Prospective cohort: 2 [131, 149]	Mixed use: 1 [97]	Not funded: 2 [66, 149]
	Cross-sectional: 3 [97, 154, 160]	Immediate effects in lab: 2 [69, 83]	Not reported: 4 [65, 97, 131, 160]
		Not reported/Unclear: 1 [160]